Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.48 |
| ▸ | VNN1 | O95497 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SPR | P35270 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873859 | 0.94 | MEN1 (0.54) | NAMPTVNN1MEN1KMT2ATSHR | |
| SCHEMBL13873815 | 0.84 | CYP2C9 (0.49) | NAMPTVNN1SPRCHRNA7KIT | |
| SCHEMBL13873799 | 0.83 | CHRNA7 (0.52) | NAMPTMEN1KMT2ACHRNA7SMN1; SMN2 | |
| SCHEMBL13873833 | 0.80 | CYP2C9 (0.57) | NAMPTCHRNA7KIT | |
| SCHEMBL13873778 | 0.80 | MEN1 (0.51) | VNN1MEN1KMT2ASPRCHRNA7 | |
| SCHEMBL13873755 | 0.79 | EPHX2 (0.57) | NAMPTMEN1KMT2ACHRNA7TSHR | |
| SCHEMBL13873609 | 0.79 | MEN1 (0.56) | NAMPTVNN1MEN1KMT2ASPR | |
| SCHEMBL13873844 | 0.79 | CYP2C9 (0.58) | NAMPTCHRNA7KIT | |
| SCHEMBL13873874 | 0.79 | EPHX2 (0.63) | NAMPTMEN1KMT2ACHRNA7SMN1; SMN2 | |
| SCHEMBL13873597 | 0.78 | EPHX2 (0.65) | NAMPTVNN1MEN1KMT2ASPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | NAMPT 1984/4885VNN1 966/4885MEN1 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.